Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomics of Tredaptive in Hong Kong Chinese patients with dyslipidemia
ChiCTR-ONC-10001038Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jan 1990
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of laropiprant in dyslipidemia and hypercholesterolemia, sponsored by Merck & Co. Primary endpoint: Genotype distribution in patients with or without flushing for common polymorphisms in GPR109A and PTGDR. Started Jan 1990; status: completed.
02
Drugs
laropiprant
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on ChiCTR-ONC-10001038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-10001038.